

What is claimed:

1. A method for identifying a compound capable of treating AIDS or an HIV-related disorder, comprising:
 - a) combining a compound to be tested with a 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777 polypeptide under conditions suitable for binding of the test compound to the polypeptide; and
 - b) detecting binding of the test compound to the polypeptide to thereby identify a compound which binds to the polypeptide, thereby identifying a compound capable of treating AIDS or an HIV-related disorder.
2. The method of claim 1, wherein the compound is selected from the group consisting of a small molecule, a peptide or an antibody.
3. The method of claim 1, wherein the polypeptide further comprises heterologous sequences.
4. The method of claim 1, wherein the polypeptide is an isolated polypeptide, a membrane-bound form of an isolated polypeptide or a cell comprising the polypeptide.
5. The method of claim 4, wherein the cell is an AIDS- or HIV-related cell.
6. The method of claim 1, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:
 - a) a competition binding assay;
 - b) an immunoassay; and
 - c) a yeast two-hybrid assay.
7. A method for identifying a compound capable of treating AIDS or an HIV-related disorder, comprising:
 - a) combining a compound to be tested with a host cell expressing a 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644,

19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777 polypeptide under conditions suitable for binding of the test compound to the polypeptide; and

b) detecting binding of the test compound to the polypeptide to thereby identify a compound which binds to the polypeptide, thereby identifying a compound capable of treating AIDS or an HIV-related disorder.

8. The method of claim 7, wherein the compound is selected from the group consisting of a small molecule, a peptide, an antibody or an antisense nucleic acid molecule.

9. The method of claim 7, wherein the polypeptide further comprises heterologous sequences.

10. The method of claim 7, wherein the host cell is an AIDS- or HIV-related cell.

11. The method of claim 7, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

- a) a competition binding assay;
- b) an immunoassay; and
- c) a yeast two-hybrid assay.

12. A method of identifying a subject having AIDS or an HIV-related disorder, or at risk for developing AIDS or an HIV-related disorder comprising:

a) contacting a sample obtained from the subject comprising polypeptides with a 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777 binding substance; and

b) detecting the presence of a polypeptide in the sample that binds to the 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777 binding substance, thereby identifying a subject having AIDS or an HIV-related disorder, or at risk for developing AIDS or an HIV-related disorder.

13. The method of claim 12, wherein the binding substance is an antibody.

14. The method of claim 12, wherein the binding substance is detectably labeled.

15. A method for treating a subject having AIDS or an HIV-related disorder characterized by aberrant 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777 polypeptide activity or aberrant 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777 nucleic acid expression comprising administering to the subject a 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777 modulator, thereby treating said subject having AIDS or an HIV-related disorder.

16. The method of claim 15, wherein the disorder is a disorder associated with but not limited to AIDS or an HIV-related disorder.

17. The method of claim 15, wherein the 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777 modulator is administered in a pharmaceutically acceptable formulation.

18. The method of claim 15, wherein the 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777 modulator is capable of modulating 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777 polypeptide activity.

19. The method of claim 18, wherein the 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777 modulator is an anti-9145, 1725, 311,

837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777 antibody.

20. The method of claim 15, wherein the 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777 modulator is capable of modulating 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777 nucleic acid expression.